Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chubb
AstraZeneca
Colorcon
Queensland Health
Deloitte
Medtronic
QuintilesIMS
Merck

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,420,676

« Back to Dashboard

Summary for Patent: 8,420,676
Title:Oxazolidinone derivatives
Abstract: The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as, Staphylococci, Enterococci and Streptococci anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.
Inventor(s): Rhee; Jae Keol (Kyonggido, KR), Im; Weon Bin (Yongin-si, KR), Cho; Chong Hwan (Yongin-si, KR), Choi; Sung Hak (Seongnam-si, KR), Lee; Tae Ho (Yongin-si, KR)
Assignee: Dong-A Pharmaceuticals Co. Ltd. (Seoul, KR)
Application Number:12/211,655
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,420,676

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cubist Pharms Llc SIVEXTRO tedizolid phosphate POWDER;IV (INFUSION) 205436-001 Jun 20, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING BACTERIAL INFECTIONS ➤ Sign Up
Cubist Pharms Llc SIVEXTRO tedizolid phosphate TABLET;ORAL 205435-001 Jun 20, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING BACTERIAL INFECTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,420,676

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2003-0093342Dec 18, 2003
South Korea10-2004-0058809Jul 27, 2004

Non-Orange Book US Patents Family Members for Patent 8,420,676

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,816,379 Oxazolidinone derivatives ➤ Sign Up
9,163,043 Oxazolidinone derivatives ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,420,676

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2010149618 ➤ Sign Up
Russian Federation 2414469 ➤ Sign Up
Russian Federation 2006125761 ➤ Sign Up
Portugal 1699784 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Dow
Queensland Health
Medtronic
Fish and Richardson
McKesson
QuintilesIMS
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.